Search

Your search keyword '"De Feo G"' showing total 365 results

Search Constraints

Start Over You searched for: Author "De Feo G" Remove constraint Author: "De Feo G"
365 results on '"De Feo G"'

Search Results

1. Risk Analysis in Healthcare Organizations: Methodological Framework and Critical Variables

2. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

5. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

6. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project)

7. Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

8. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

9. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

11. Development and validation of combined symptom-medication scores for allergic rhinitis*

12. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

13. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data

14. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

17. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

18. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

19. Adherence to treatment in allergic rhinitis using mobile technology. the mask study

20. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

22. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

23. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

25. Treatment of allergic rhinitis during and outside the pollen season using mobile technology : A MASK study

26. Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing

28. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

29. ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

30. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

31. Evaluation of Clinico-Pathological Alterations Including Some Leukocyte Ratios and Survival Rate in Dogs with IMHA Transfused and Not Transfused: A Retrospective Study

33. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

34. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study

35. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study

36. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018) : Change management in allergic rhinitis and asthma multimorbidity using mobile technology

37. Adherence to treatment in allergic rhinitis using mobile technology : The MASK Study

38. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

39. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.

40. ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

41. ARIA Phase 4 (2018): change management in allergic rhinitis and asthma multimorbidity using mobile technology

42. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)

43. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

44. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

46. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)

47. ARIA Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

48. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response

49. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

Catalog

Books, media, physical & digital resources